دورية أكاديمية
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
| العنوان: | Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. |
|---|---|
| المؤلفون: | Hegi ME; Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland. Monika.Hegi@chuv.ch, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MC, Hartmann C, von Deimling A, Martinet D, Besuchet Schmutz N, Diserens AC, Hamou MF, Bady P, Weller M, van den Bent MJ, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P |
| مؤلفون مشاركون: | European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group |
| المصدر: | Acta neuropathologica [Acta Neuropathol] 2012 Jun; Vol. 123 (6), pp. 841-52. Date of Electronic Publication: 2012 Jan 15. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0412041 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0533 (Electronic) Linking ISSN: 00016322 NLM ISO Abbreviation: Acta Neuropathol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin : Springer Verlag |
| مواضيع طبية MeSH: | Brain Neoplasms/*pathology , Glioblastoma/*pathology , Oligodendroglioma/*pathology, Adolescent ; Adult ; Aged ; Brain Neoplasms/genetics ; Brain Neoplasms/therapy ; Chemoradiotherapy ; Clinical Trials, Phase III as Topic ; DNA Methylation ; Dacarbazine/analogs & derivatives ; Dacarbazine/therapeutic use ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Female ; Glioblastoma/genetics ; Glioblastoma/therapy ; Humans ; Male ; Middle Aged ; Mutation ; Oligodendroglioma/genetics ; Oligodendroglioma/therapy ; Prognosis ; Survival Analysis ; Temozolomide ; Treatment Outcome ; Young Adult |
| مستخلص: | Glioblastoma (GBM) is a morphologically heterogeneous tumor type with a median survival of only 15 months in clinical trial populations. However, survival varies greatly among patients. As part of a central pathology review, we addressed the question if patients with GBM displaying distinct morphologic features respond differently to combined chemo-radiotherapy with temozolomide. Morphologic features were systematically recorded for 360 cases with particular focus on the presence of an oligodendroglioma-like component and respective correlations with outcome and relevant molecular markers. GBM with an oligodendroglioma-like component (GBM-O) represented 15% of all confirmed GBM (52/339) and was not associated with a more favorable outcome. GBM-O encompassed a pathogenetically heterogeneous group, significantly enriched for IDH1 mutations (19 vs. 3%, p = 0.003) and EGFR amplifications (71 vs. 48%, p = 0.04) compared with other GBM, while co-deletion of 1p/19q was found in only one case and the MGMT methylation frequency was alike (47 vs. 46%). Expression profiles classified most of the GBM-O into two subtypes, 36% (5/14 evaluable) as proneural and 43% as classical GBM. The detection of pseudo-palisading necrosis (PPN) was associated with benefit from chemotherapy (p = 0.0002), while no such effect was present in the absence of PPN (p = 0.86). In the adjusted interaction model including clinical prognostic factors and MGMT status, PPN was borderline nonsignificant (p = 0.063). Taken together, recognition of an oligodendroglioma-like component in an otherwise classic GBM identifies a pathogenetically mixed group without prognostic significance. However, the presence of PPN may indicate biological features of clinical relevance for further improvement of therapy. |
| معلومات مُعتمدة: | 2U10 CA011488-41 United States CA NCI NIH HHS; 5U10 CA11488-30 United States CA NCI NIH HHS |
| المشرفين على المادة: | 7GR28W0FJI (Dacarbazine) EC 2.7.10.1 (EGFR protein, human) EC 2.7.10.1 (ErbB Receptors) YF1K15M17Y (Temozolomide) |
| تواريخ الأحداث: | Date Created: 20120118 Date Completed: 20120924 Latest Revision: 20220409 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1007/s00401-011-0938-4 |
| PMID: | 22249618 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-0533 |
|---|---|
| DOI: | 10.1007/s00401-011-0938-4 |